Skip to main content

STERIS Value Stock - Dividend - Research Selection

Steris

ISIN: IE00BFY8C754 , WKN: A2PGLV

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The company was founded in 1985 and is based in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Is Wall Street Bullish or Bearish on STERIS Stock?

2026-02-20
Despite STERIS' outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Tracking Al Gore's Generation Investment Management Portfolio - Q4 2025 Update

2026-02-18

STERIS plc (STE) Remains in Focus as Analysts Reaffirm Confidence

2026-02-15
STERIS plc (NYSE:STE) is one of the best medical technology stocks to invest in. On February 5, Citizens reiterated its Market Outperform rating on STERIS plc (NYSE:STE) and kept the $280 price target on the shares. The firm made this move in reaction to STERIS’s Q3 FY2026 financial results. STERIS beat revenue expectations by about […]

The 5 Most Interesting Analyst Questions From STERIS’s Q4 Earnings Call

2026-02-11
STERIS’s fourth quarter results received a negative reaction from the market despite surpassing Wall Street’s revenue expectations and reporting adjusted earnings per share in line with consensus. Management attributed the quarter’s performance to broad-based volume growth across all segments, with particular strength in healthcare services and consumables. However, CEO Daniel Carestio acknowledged that margin pressures from increased tariffs and inflation more than offset the positive impacts o

Steris (STE) International Revenue Performance Explored

2026-02-09
Explore Steris' (STE) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Stronger Earnings And Dividend Payout Could Be A Game Changer For STERIS (STE)

2026-02-09
STERIS plc has reported past third-quarter 2025 results showing sales of US$1,496.2 million and net income of US$192.9 million, with earnings per share rising versus the prior year, and also confirmed a quarterly dividend of US$0.63 per share payable on March 19, 2026. The combination of higher sales and earnings over both the quarter and the first nine months of the fiscal year highlights ongoing operational momentum across STERIS’s business. With this backdrop of improved earnings and a...

STERIS Q3 Earnings Call Highlights

2026-02-07
STERIS (NYSE:STE) executives highlighted broad-based third-quarter fiscal 2026 growth, improved earnings, and ongoing tariff headwinds during the company’s earnings call, while maintaining full-year guidance and pointing to a more challenging comparison in the fourth quarter. Third-quarter results:

Dividend Champion, Contender, And Challenger Highlights: Week Of February 8

2026-02-06
Get this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates. Read the full analysis here.

STERIS: A Bump In The Road For A Reliable Name

2026-02-06
STERIS plc is rated a Buy, offers a resilient, high-quality business model with some premium valuation. Learn more about STE stock here.

Steris PLC (STE) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Tariff Challenges

2026-02-05
Steris PLC (STE) reports a 9% revenue increase and robust free cash flow, while navigating tariff impacts and maintaining fiscal 2026 outlook.